Report Feature
The future of the nuclear medicine/radiopharmaceutical market looks promising with opportunities in the hospitals, diagnostic centers, and research institutes. The global nuclear medicine/radiopharma
ceutical market is expected to grow with a CAGR of 9% from 2019 to 2024. The major drivers for this market are increasing incidence and prevalence of cancer and cardiovascular diseases (CVD) and growing investment through public private partnerships to modernize diagnostic imaging centers, alpha radioimmunotherapy (RIT) based targeted cancer treatment, and advances in radiotracers.A report of more than 150-pages is developed to help in your business decisions. Sample figures with some insights are shown below. To learn the scope of, benefits, companies researched and other details of nuclear medicine/radiopharmaceuticals market report download the report brochure
The study includes the nuclear medicine/radiopharmaceutical market size and forecast for the global nuclear medicine/radiopharmaceutical market through 2024, segmented by product type, application, end user, and region as follows:
By Product Type [$M shipment analysis for 2013 – 2024]:
-
Diagnostic Nuclear Medicine/Radiopharmaceutical
- SPECT Radiopharmaceutical
- PET Radiopharmaceutical
-
Therapeutic Nuclear Medicine/Radiopharmaceutical
- Beta Emitters
- Alpha Emitters
- Brachytherapy
By Application [$M shipment analysis for 2013 – 2024]:
- Cardiology
- Lymphoma
- Thyroid
- Neurology
- Oncology
- Bone Metastasis
- Endocrine Tumors
By End User [$M shipment analysis for 2013 – 2024]:
- Hospitals and Diagnostic Centers
- Research Institutes
By Region [$M shipment analysis for 2013 – 2024]:
-
North America
- United States
- Canada
- Mexico
-
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
-
Asia-Pacific
- China
- India
- Japan
-
Rest of the World (ROW)
- Brazil
Some of the nuclear medicine/radiopharmaceutical companies profiled in this report include Cardinal Health, Mallinckrodt, GE Healthcare, Lantheus Medical Imaging, Bayer, Bracco Imaging, Eczacibasi-Monrol Nuclear Products, Noridian, and Iba Molecular.
Some of the features of "Global Nuclear Medicine/Radiopharmaceuticals Market 2019-2024: Trends, Forecast, and Opportunity Analysis" include
- Market size estimates:Global nuclear medicine/radiopharmaceuticals market size estimation in terms of value ($M) shipment.
- Trend and forecast analysis:Market trend (2013-2018) and forecast (2019-2024) by segments and region.
- Segmentation analysis:Global market size by various applications such as by product type, application, end user, and region.
- Regional analysis:Global nuclear medicine/radiopharmaceuticals market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
- Growth opportunities:Analysis on growth opportunities in different applications and regions for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
- Strategic analysis:This includes M&A, new product development, and competitive landscape for nuclear medicine/radiopharmaceuticals in the global nuclear medicine/radiopharmaceuticals market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Table of Contents
1. Executive Summary 2. Market Background and Classifications 2.1: Introduction, Background, and Classifications 2.2: Supply Chain 2.3: Industry Drivers and Challenges
5. Competitor Analysis 5.1: Product Portfolio Analysis 5.2: Market Share Analysis 5.3: Operational Integration 5.4: Geographical Reach 5.5: Porter’s Five Forces Analysis
7. Company Profiles of Leading Players 7.1: Cardinal Health 7.2: Mallinckrodt 7.3: GE Healthcare 7.4: Lantheus Medical Imaging 7.5: Bayer 7.6: Bracco Imaging 7.7: Eczacibasi-Monrol Nuclear Products 7.8: Noridion 7.9: IBA Molecular
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
Key Questions
- • What are some of the most promising potential, high-growth opportunities for the global nuclear medicine/radiopharmaceutical market by product type (diagnostic nuclear medicine/radiopharmaceutical (SPECT radiopharmaceutical, PET radiopharmaceutical), and therapeutic nuclear medicine/radiopharmaceutical (beta emitters, alpha emitters and brachytherapy), application (Cardiology, lymphoma, thyroid, oncology, neurology, bone metastasis, endocrine tumors), end user (hospitals and diagnostic centers, and research institutes), and region (North America, Asia-Pacific, Europe, Rest of the World(ROW))?
- • Which segments will grow at a faster pace and why?
- • Which regions will grow at a faster pace and why?
- • What are the key factors affecting market dynamics? What are the drivers and challenges of the nuclear medicine/radiopharmaceutical market?
- • What are the business risks and threats to the nuclear medicine/radiopharmaceutical market?
- • What are emerging trends in this nuclear medicine/radiopharmaceutical market and the reasons behind them?
- • What are some changing demands of customers in the nuclear medicine/radiopharmaceutical market?
- • What are the new developments in the nuclear medicine/radiopharmaceutical market? Which companies are leading these developments?
- • Who are the major players in this nuclear medicine/radiopharmaceutical market? What strategic initiatives are being implemented by key players for business growth?
- • What are some of the competitive products and processes in this nuclear medicine/radiopharmaceutical area and how big of a threat do they pose for loss of market share via material or product substitution?
- • What M&A activities have taken place in the last 5 years in this nuclear medicine/radiopharmaceutical market?
